Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of more than $760 billion. It has been soaring in recent years due to the success of its highly effective GLP-1 products: Mounjaro for diabetes and Zepbound for weight loss.Whether it can continue rallying higher and potentially hit a $1 trillion valuation in the future, however, will likely depend on the success of its GLP-1 products, as that has attracted many growth investors. But many other companies have also been aggressively targeting the space, looking to boost their own sales and profits from the massive interest in weight loss drugs.One company recently announced its interest in being a top player in the GLP-1 market, and it could offer serious competition for Eli Lilly: Roche Holding (OTC: RHHBY)Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool